GlaxoSmithKline Q3 Profit Surges 5x to Rs 229 cr - Business News
GlaxoSmithKline Pharmaceuticals reports a five-fold jump in net profit for the third quarter ending December 31, 2024, reaching Rs 229 crore. Revenue also increased to Rs 949 crore.
New Delhi, Feb 14 (PTI) GlaxoSmithKline Pharmaceuticals on Friday said its net profit increased over five-fold to Rs 229 crore for the third quarter ended December 31, 2024.
The drug firm reported a net profit of Rs 45 crore for the October-December quarter of last fiscal.
Revenue from operations rose to Rs 949 crore for the third quarter, as compared to Rs 805 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a statement.
"Our strong third-quarter results reflect our unwavering commitment to deliver innovative healthcare solutions to patients across India," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar stated.
By focusing on core brands and accelerating digital transformation through innovative go-to-market strategies, the company continues to strengthen its market presence while ensuring broader access to medicines and vaccines, he added.
The company saw strong performance across key product portfolios during the quarter, the drug firm said.
Flagship brands within the general medicines portfolio including Augmentin, Ceftum, and T-bact strengthened their market positions with share gains, it added.
In the vaccines segment, GSK maintained its leadership in the self-pay private market for paediatric vaccines, it said.
Shares of the company ended 1.11 per cent up at Rs 2,017.75 apiece on BSE.
The drug firm reported a net profit of Rs 45 crore for the October-December quarter of last fiscal.
Revenue from operations rose to Rs 949 crore for the third quarter, as compared to Rs 805 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a statement.
"Our strong third-quarter results reflect our unwavering commitment to deliver innovative healthcare solutions to patients across India," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar stated.
By focusing on core brands and accelerating digital transformation through innovative go-to-market strategies, the company continues to strengthen its market presence while ensuring broader access to medicines and vaccines, he added.
The company saw strong performance across key product portfolios during the quarter, the drug firm said.
Flagship brands within the general medicines portfolio including Augmentin, Ceftum, and T-bact strengthened their market positions with share gains, it added.
In the vaccines segment, GSK maintained its leadership in the self-pay private market for paediatric vaccines, it said.
Shares of the company ended 1.11 per cent up at Rs 2,017.75 apiece on BSE.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 7.04 ( -1.68)
- 102363129
- Srestha Finvest
- 0.51 ( -3.77)
- 22605309
- GMR Airports
- 76.30 (+ 0.83)
- 19768792
- Bajaj HindusthanSuga
- 19.57 ( -2.59)
- 15088109
- G G Engineering
- 0.90 ( -3.23)
- 13176176
MORE NEWS
© 2025 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback